Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

China Radioligand Therapy Market

ID: MRFR/Pharma/50338-HCR
200 Pages
Rahul Gotadki
Last Updated: March 28, 2026

China Radioligand Therapy RLT Market Research Report: Size, Share, Trend Analysis By Isotope (Fluorine – 18, Gallium – 68, Lutetium – 177, Others), By Targeted Receptor (Prostate-specific Membrane Antigen (PSMA), Somatostatin Receptor (SSTR), Epidermal Growth Factor Receptor (EGFR), Others), By Indication (Prostate Cancer, Neuroendocrine Tumors (NETs), Breast Cancer, Others) and By End Users (Hospitals & Clinics, Diagnostic Centers, Others) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

China Radioligand Therapy Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Application (USD Billion)
  49.     4.1.1 Oncology
  50.     4.1.2 Cardiology
  51.     4.1.3 Neurology
  52.     4.1.4 Endocrinology
  53.   4.2 Healthcare, BY Type of Radioligand (USD Billion)
  54.     4.2.1 Alpha Emitters
  55.     4.2.2 Beta Emitters
  56.     4.2.3 Auger Electron Emitters
  57.     4.2.4 Radionuclide Therapy
  58.   4.3 Healthcare, BY Administration Route (USD Billion)
  59.     4.3.1 Intravenous
  60.     4.3.2 Oral
  61.     4.3.3 Subcutaneous
  62.   4.4 Healthcare, BY Target Disease (USD Billion)
  63.     4.4.1 Prostate Cancer
  64.     4.4.2 Neuroendocrine Tumors
  65.     4.4.3 Lymphoma
  66.     4.4.4 Thyroid Cancer
  67.   4.5 Healthcare, BY Patient Demographics (USD Billion)
  68.     4.5.1 Pediatric Patients
  69.     4.5.2 Adult Patients
  70.     4.5.3 Geriatric Patients
  71. 5 SECTION V: COMPETITIVE ANALYSIS
  72.   5.1 Competitive Landscape
  73.     5.1.1 Overview
  74.     5.1.2 Competitive Analysis
  75.     5.1.3 Market share Analysis
  76.     5.1.4 Major Growth Strategy in the Healthcare
  77.     5.1.5 Competitive Benchmarking
  78.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  79.     5.1.7 Key developments and growth strategies
  80.       5.1.7.1 New Product Launch/Service Deployment
  81.       5.1.7.2 Merger & Acquisitions
  82.       5.1.7.3 Joint Ventures
  83.     5.1.8 Major Players Financial Matrix
  84.       5.1.8.1 Sales and Operating Income
  85.       5.1.8.2 Major Players R&D Expenditure. 2023
  86.   5.2 Company Profiles
  87.     5.2.1 Novartis (CH)
  88.       5.2.1.1 Financial Overview
  89.       5.2.1.2 Products Offered
  90.       5.2.1.3 Key Developments
  91.       5.2.1.4 SWOT Analysis
  92.       5.2.1.5 Key Strategies
  93.     5.2.2 Bayer (DE)
  94.       5.2.2.1 Financial Overview
  95.       5.2.2.2 Products Offered
  96.       5.2.2.3 Key Developments
  97.       5.2.2.4 SWOT Analysis
  98.       5.2.2.5 Key Strategies
  99.     5.2.3 Eli Lilly (US)
  100.       5.2.3.1 Financial Overview
  101.       5.2.3.2 Products Offered
  102.       5.2.3.3 Key Developments
  103.       5.2.3.4 SWOT Analysis
  104.       5.2.3.5 Key Strategies
  105.     5.2.4 AstraZeneca (GB)
  106.       5.2.4.1 Financial Overview
  107.       5.2.4.2 Products Offered
  108.       5.2.4.3 Key Developments
  109.       5.2.4.4 SWOT Analysis
  110.       5.2.4.5 Key Strategies
  111.     5.2.5 Bristol-Myers Squibb (US)
  112.       5.2.5.1 Financial Overview
  113.       5.2.5.2 Products Offered
  114.       5.2.5.3 Key Developments
  115.       5.2.5.4 SWOT Analysis
  116.       5.2.5.5 Key Strategies
  117.     5.2.6 Pfizer (US)
  118.       5.2.6.1 Financial Overview
  119.       5.2.6.2 Products Offered
  120.       5.2.6.3 Key Developments
  121.       5.2.6.4 SWOT Analysis
  122.       5.2.6.5 Key Strategies
  123.     5.2.7 Ipsen (FR)
  124.       5.2.7.1 Financial Overview
  125.       5.2.7.2 Products Offered
  126.       5.2.7.3 Key Developments
  127.       5.2.7.4 SWOT Analysis
  128.       5.2.7.5 Key Strategies
  129.     5.2.8 Merck KGaA (DE)
  130.       5.2.8.1 Financial Overview
  131.       5.2.8.2 Products Offered
  132.       5.2.8.3 Key Developments
  133.       5.2.8.4 SWOT Analysis
  134.       5.2.8.5 Key Strategies
  135.     5.2.9 Siemens Healthineers (DE)
  136.       5.2.9.1 Financial Overview
  137.       5.2.9.2 Products Offered
  138.       5.2.9.3 Key Developments
  139.       5.2.9.4 SWOT Analysis
  140.       5.2.9.5 Key Strategies
  141.   5.3 Appendix
  142.     5.3.1 References
  143.     5.3.2 Related Reports
  144. 6 LIST OF FIGURES
  145.   6.1 MARKET SYNOPSIS
  146.   6.2 CHINA MARKET ANALYSIS BY APPLICATION
  147.   6.3 CHINA MARKET ANALYSIS BY TYPE OF RADIOLIGAND
  148.   6.4 CHINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
  149.   6.5 CHINA MARKET ANALYSIS BY TARGET DISEASE
  150.   6.6 CHINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS
  151.   6.7 KEY BUYING CRITERIA OF HEALTHCARE
  152.   6.8 RESEARCH PROCESS OF MRFR
  153.   6.9 DRO ANALYSIS OF HEALTHCARE
  154.   6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  155.   6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  156.   6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
  157.   6.13 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
  158.   6.14 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
  159.   6.15 HEALTHCARE, BY TYPE OF RADIOLIGAND, 2024 (% SHARE)
  160.   6.16 HEALTHCARE, BY TYPE OF RADIOLIGAND, 2024 TO 2035 (USD Billion)
  161.   6.17 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
  162.   6.18 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion)
  163.   6.19 HEALTHCARE, BY TARGET DISEASE, 2024 (% SHARE)
  164.   6.20 HEALTHCARE, BY TARGET DISEASE, 2024 TO 2035 (USD Billion)
  165.   6.21 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE)
  166.   6.22 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Billion)
  167.   6.23 BENCHMARKING OF MAJOR COMPETITORS
  168. 7 LIST OF TABLES
  169.   7.1 LIST OF ASSUMPTIONS
  170.     7.1.1
  171.   7.2 China MARKET SIZE ESTIMATES; FORECAST
  172.     7.2.1 BY APPLICATION, 2026-2035 (USD Billion)
  173.     7.2.2 BY TYPE OF RADIOLIGAND, 2026-2035 (USD Billion)
  174.     7.2.3 BY ADMINISTRATION ROUTE, 2026-2035 (USD Billion)
  175.     7.2.4 BY TARGET DISEASE, 2026-2035 (USD Billion)
  176.     7.2.5 BY PATIENT DEMOGRAPHICS, 2026-2035 (USD Billion)
  177.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  178.     7.3.1
  179.   7.4 ACQUISITION/PARTNERSHIP
  180.     7.4.1

China Healthcare Market Segmentation

Healthcare By Application (USD Billion, 2026-2035)

  • Oncology
  • Cardiology
  • Neurology
  • Endocrinology

Healthcare By Type of Radioligand (USD Billion, 2026-2035)

  • Alpha Emitters
  • Beta Emitters
  • Auger Electron Emitters
  • Radionuclide Therapy

Healthcare By Administration Route (USD Billion, 2026-2035)

  • Intravenous
  • Oral
  • Subcutaneous

Healthcare By Target Disease (USD Billion, 2026-2035)

  • Prostate Cancer
  • Neuroendocrine Tumors
  • Lymphoma
  • Thyroid Cancer

Healthcare By Patient Demographics (USD Billion, 2026-2035)

  • Pediatric Patients
  • Adult Patients
  • Geriatric Patients

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓